Acurx Pharmaceuticals (ACXP) Stock Explodes 218% on CDI Clinical Trial Breakthrough

Key Takeaways

• Shares of Acurx Pharmaceuticals skyrocketed more than 218% this week following news of a clinical trial initiation for ibezapolstat, its primary antibiotic candidate.
• Phase 2 data revealed ibezapolstat achieved a 96% cure rate for C. difficile infection (CDI), with no recurrence observed among successfully treated patients.
• A 20-patient open-label pilot study targeting recurrent CDI patients is now underway, setting the foundation for an upcoming Phase 3 registration trial.
• Both U.S. and European regulatory agencies have provided Acurx with a defined pathway to commence global Phase 3 clinical studies.
• The company’s annual net loss for 2025 decreased to $8.0 million from $14.1 million, while cash reserves rose to $7.6 million.

Acurx Pharmaceuticals (ACXP) delivered one of the most dramatic stock performances in the biotech sector this year. Shares surged more than 218% over a five-day period after the company unveiled its new clinical trial initiative for ibezapolstat, a novel antibiotic designed to combat C. difficile infection.

Acurx Pharmaceuticals, Inc., ACXP

The majority of gains materialized after a Monday press release that established the framework for Phase 3 development. When Friday arrived, shares tacked on an additional 3.59% during pre-market hours following the company’s fourth-quarter earnings announcement.

C. difficile infection, commonly abbreviated as CDI, represents a bacterial infection of the gastrointestinal tract notorious for its tendency to recur. Among patients experiencing three or more episodes within a 12-month span, effective treatment alternatives remain scarce, and recurrence rates pose a persistent challenge.

The Phase 2 results for ibezapolstat delivered compelling data points for market participants. The compound achieved a 96% clinical cure rate across 26 patients diagnosed with acute CDI. Even more noteworthy — every patient who achieved clinical cure remained infection-free throughout the entire follow-up window.

This dual capability of both treating active infection and preventing subsequent recurrence represents what Acurx considers ibezapolstat’s competitive advantage. Existing therapies typically address the immediate infection without meaningfully reducing recurrence risk.

The biotech firm is now initiating a 20-patient open-label pilot study concentrated exclusively on individuals with multiply-recurrent CDI — defined as patients who have experienced a minimum of three episodes over the preceding 12 months. Data generated from this pilot investigation will inform the architecture of the pivotal Phase 3 registration trial.

Regulatory Pathway Confirmed

Among this week’s most significant developments was the verification that regulatory authorities in both the United States and Europe have established a well-defined framework for Acurx to initiate multinational Phase 3 investigations. For a small-capitalization biotechnology company, this type of bilateral regulatory transparency eliminates a substantial source of uncertainty.

This also demonstrates that the company’s strategy extends beyond purely domestic clinical work — the blueprint incorporates international reach from the outset.

In February 2026, Acurx secured an additional patent covering its Pol IIIC inhibitor technology, extending intellectual property protection until December 2039. Should the compound ultimately reach commercialization, that represents substantial exclusivity duration.

Fourth Quarter Financial Results: Deficit Reduction

Regarding financial performance, Acurx disclosed a Q4 2025 loss of $5.32 per share, representing an increase from the $3.29 per-share loss recorded in Q4 2024. However, the annual financial trajectory presents a more favorable narrative.

For the complete 2025 fiscal year, net losses totaled $8.0 million versus $14.1 million in 2024 — representing substantial improvement. Research and development expenditures declined to $0.3 million from $0.8 million, while general and administrative costs decreased to $1.3 million from $2.0 million.

Liquidity also strengthened. Acurx concluded the period ending December 31, 2025 with $7.6 million in cash, an increase from $3.7 million one year prior. This positions the company on firmer footing as it enters an active trial phase.

Two Wall Street analysts presently assign ACXP a Moderate Buy rating, establishing a consensus 12-month price target of $17.50.

As of Friday morning’s earnings disclosure, the stock was registering a 3.59% pre-market advance following confirmation of the new recurrent CDI trial launch.

The post Acurx Pharmaceuticals (ACXP) Stock Explodes 218% on CDI Clinical Trial Breakthrough appeared first on Blockonomi.